Archemix and Dicerna collaborate on RNAi therapeutics
This article was originally published in Scrip
Executive Summary
Archemix and Dicerna Pharmaceuticals are to collaborate on the development of therapeutics which combine the intracellular delivery capabilities of Archemix's aptamers and the gene silencing characteristics of Dicerna's dicer substrate RNA (DsiRNA) molecules.